BMED iShares Health Innovation Active ETF

ETF on NYSE (US) · Actively managed · Listing

Daily holdings file Nov 16, 2026 Published at ishares.com
Book $14.3M 59 positions
Line items 59
In top 10 47%
Largest holding: Gilead Sciences, Inc. ($843K) 5.9%
Portfolio date Nov 16, 2026

Changes appear once four weeks of holdings are on file.

Largest holding: Gilead Sciences, Inc., 5,033 shares ($843K).

Gilead Sciences, Inc.: 5.9% Moderna, Inc.: 5.2% Danaher Corporation: 5.2% BLK CSH FND TREASURY SL AGENCY: 5.0% AbbVie Inc.: 5.0% Edwards Lifesciences Corporation: 4.4% Thermo Fisher Scientific Inc: 4.4% Merck & Company, Inc.: 4.2% Biogen Inc.: 3.8% Mettler-Toledo International, Inc.: 3.7% The other 49 positions: 53.3% $14.3M Holdings value
Current positions Top 10 % of book
Gilead Sciences, Inc. GILD $843K 5.9%
Moderna, Inc. MRNA $748K 5.2%
Danaher Corporation DHR $743K 5.2%
BLK CSH FND TREASURY SL AGENCY XTSLA $720K 5.0%
AbbVie Inc. ABBV $716K 5.0%
Edwards Lifesciences Corporation EW $626K 4.4%
Thermo Fisher Scientific Inc TMO $624K 4.4%
Merck & Company, Inc. MRK $602K 4.2%
Biogen Inc. BIIB $541K 3.8%
Mettler-Toledo International, Inc. MTD $525K 3.7%

Slices are % of holdings value.

Healthcare: 83.3% Technology: 7.1% Financial Services: 0.8% Unclassified: 8.8% 3 sectors
Sectors % of long value
Healthcare 83.3%
Technology 7.1%
Financial Services 0.8%
Unclassified 8.8%
Biotechnology: 41.7% Drug Manufacturers - General: 14.4% Medical Devices: 11.4% Medical Instruments & Supplies: 8.8% Scientific & Technical Instruments: 4.3% Health Information Services: 4.3% Software - Application: 2.8% Other (2): 3.5% Unclassified: 8.8% 9 industries
Industries % of long value
Biotechnology 41.7%
Drug Manufacturers - General 14.4%
Medical Devices 11.4%
Medical Instruments & Supplies 8.8%
Scientific & Technical Instruments 4.3%
Health Information Services 4.3%
Software - Application 2.8%
Other (2) 3.5%
Unclassified 8.8%

Source: the fund's own published holdings, the portfolio of Nov 16, 2026 (ishares.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The iShares Health Innovation Active ETF (the "Fund") seeks to maximize total return.

Principal investment strategies

Under normal market conditions, the Fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. Investments in derivatives are counted toward the Fund's 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one or more market risk factors associated with such securities. The Fund seeks to invest in innovative and emerging companies in health sciences. The Fund will consider a company to be principally engaged in the health sciences group of industries if (i) it is classified in an industry within the health sciences group of industries by a third-party industry classification system or (ii) it is not classified in any industry by such third-party industry classification system and BFA determines that the company is principally engaged in the health sciences group of industries. Companies in the health sciences group of industries include healthcare providers as well as businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment or services or that provide support services to these companies. These companies also include those that own or operate health facilities and hospitals or provide related administrative, management or S-2 financial support. Other companies in the health sciences group of industries in which the Fund may invest include: clinical testing laboratories; diagnostics; hospital, laboratory or physician ancillary products and support services; rehabilitation services; employer health insurance management services; and vendors of goods and services specifically to companies engaged in the health sciences. The Fund will concentrate its investments in the health sciences group of industries. While the Fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants. Non-human health sciences companies include those engaged in the development, production or distribution of products or services that: increase crop, animal and animal product yields by enhancing growth or increasing disease resistance; improve agricultural product characteristics, such as taste, appearance, nutritional content and shelf life; reduce the cost of producing agricultural products; or improve pet health. The Fund may invest in companies of any market capitalization located anywhere in the world, including companies located in emerging markets. The Fund will focus its investments in mid- and small-capitalization companies. Foreign securities in which the Fund may invest may be U.S. dollar-denominated or non-U.S. dollar-denominated. The Fund invests primarily in equity securities, including common stocks, preferred stocks, warrants and depository receipts, of health sciences companies and equity interests in real estate investment trusts ("REITs") that own hospitals. The Fund may invest in shares of companies through initial public offerings ("IPOs"). The Fund may also purchase convertible securities. The Fund may purchase and sell futures contracts, enter into various interest rate transactions such as swaps, caps, floors or collars, currency transactions such as currency forward contracts, currency futures contracts, currency swaps or options on currency or currency futures and swap contracts (including, but not limited to, credit default swaps) and may purchase and sell exchange-listed and over-the-counter ("OTC") put and call options on securities and swap contracts, financial indices and futures contracts and use other derivative instruments or management techniques (collectively, "Strategic Transactions").

Management and Contact

Adviser
BlackRock Fund Advisors
Portfolio managers

Erin Xie and Xiang Liu (the "Portfolio Managers") are jointly and primarily responsible for the day-to-day management of the Fund.

Ms. Xie and Mr. Liu have been Portfolio Managers of the Fund since September 2020.

Phone
1-800-474-2737

Track Record as of Jul 31, 2025

1 Year Since Inception
Return Before Taxes )% 1.81% 0.15%
Return after Taxes on Distributions1 )% 1.81% 0.15%
Return after Taxes on Distributions and Sale of Fund Shares1 )% 1.07% 0.11%
MSCI ACWI Index (Net)2,3 (Index returns do not reflect deductions for fees, expenses or taxes, except for withholding taxes on r 17.49% 11.69%
STOXX Global Breakthrough Healthcare Index (Net)3,4 (Index returns do not reflect deductions for fees, expenses or taxes, except 1.61% 2.31%

Holdings as of Nov 16, 2026

61 lines, 49 linked, weights sum to 100.01% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
GILEAD SCIENCES GILD Equity 5,033 0 5.89% $ 843.43K
MODERNA MRNA Equity 3,476 0 5.22% $ 748.279K
DANAHER DHR Equity 3,232 0 5.19% $ 743.069K
BLK CSH FND TREASURY SL AGENCY
XTSLA Money market 720,000 0 5.03% $ 720K
ABBVIE ABBV Equity 2,431 0 5.00% $ 716.051K
EDWARDS LIFESCIENCES EW Equity 5,846 0 4.37% $ 626.165K
THERMO FISHER SCIENTIFIC TMO Equity 902 0 4.35% $ 623.58K
BIOGEN BIIB Equity 2,150 0 3.78% $ 541.048K
METTLER TOLEDO MTD Equity 304 0 3.67% $ 525.087K
IQVIA HOLDINGS INC IQV Equity 1,923 0 3.55% $ 509.076K
VERTEX PHARMACEUTICALS VRTX Equity 884 0 3.32% $ 475.406K
MERCK & CO INC MRK Equity 2,943 +1,868 2.97% $ 425.146K
ROCHE PS PAR AG ROP Equity 853 0 2.90% $ 416.055K
GENMAB SPONSORED ADR GMAB Equity 7,231 0 2.60% $ 372.903K
AMGEN INC AMGN Equity 802 0 2.59% $ 370.781K
AGILENT TECHNOLOGIES INC A Equity 1,973 0 2.38% $ 341.171K
NEUROCRINE BIOSCIENCES NBIX Equity 1,990 0 2.30% $ 328.967K
WATERS CORP WAT Equity 710 0 2.25% $ 321.928K
DEXCOM INC DXCM Equity 3,881 0 2.21% $ 316.728K
USD CASH
USD Cash short -305,676 +91,174 -2.13% $ -305.676K
ARGENX SE ADR ARGX Equity 277 0 1.84% $ 263.413K
HALOZYME THERAPEUTICS HALO Equity 2,531 0 1.70% $ 244.242K
CHARLES RIVER LABORATORIES INTERNA CRL Equity 689 0 1.61% $ 231.173K
INTUITIVE SURGICAL ISRG Equity 486 0 1.49% $ 212.747K
ZIMMER BIOMET HOLDINGS ZBH Equity 2,076 0 1.47% $ 210.527K
TEVA PHARMACEUTICAL INDUSTRIES TEVA Equity 4,924 0 1.46% $ 209.615K
GALDERMA GROUP N AG
GALD Equity 896 0 1.42% $ 203.94K
ROIVANT SCIENCES LTD ROIV Equity 5,171 0 1.39% $ 199.652K
ILLUMINA INC ILMN Equity 995 0 1.38% $ 197.01K
PFIZER PFE Equity 6,812 −547 1.37% $ 196.594K
BRISTOL MYERS SQUIBB BMY Equity 3,058 0 1.34% $ 192.44K
NOVARTIS AG
NOVN Equity 1,171 0 1.32% $ 189.448K
JOHNSON & JOHNSON JNJ Equity 650 0 1.28% $ 183.658K
MERCK MRK Equity 1,075 0 1.24% $ 177.117K
HKD CASH
HKD Cash 1,347,832 +1,347,682 1.20% $ 171.79K
GUARDANT HEALTH GH Equity 1,166 0 1.17% $ 167.939K
CYTOKINETICS CYTK Equity 2,888 0 1.07% $ 153.555K
BIOMARIN PHARMACEUTICAL BMRN Equity 2,533 0 1.03% $ 146.889K
UCB SA UCB Equity 370 0 0.84% $ 120.171K
TEMPUS AI CLASS A TEM Equity 1,749 0 0.79% $ 113.265K
ABBOTT LABORATORIES ABT Equity 1,027 −719 0.77% $ 110.351K
PROTAGONIST THERAPEUTICS PTGX Equity 866 0 0.75% $ 108.103K
BRUKER BRKR Equity 1,648 0 0.70% $ 99.902K
AXSOME THERAPEUTICS AXSM Equity 721 0 0.69% $ 98.784K
VIRIDIAN THERAPEUTICS ORS VRDN Equity 3,067 0 0.64% $ 91.397K
ALKERMES ALKS Equity 1,902 0 0.62% $ 88.5K
DIANTHUS THERAPEUTICS DNTH Equity 890 0 0.56% $ 79.7K
PTC THERAPEUTICS PTCT Equity 1,001 0 0.43% $ 61.031K
MBX BIOSCIENCES MBX Equity 1,103 0 0.41% $ 58.591K
COGENT BIOSCIENCES COGT Equity 1,813 0 0.35% $ 49.749K
SAGIMET BIOSCIENCES SERIES A SGMT Equity 1,875 0 0.13% $ 18.994K
SUMMIT THERAPEUTICS SMMT Equity 706 0 0.06% $ 8,344.92
EIKON THERAPEUTICS EIKN Equity 1,392 0 0.05% $ 7,495.92
ABIOMED CVRS
- Equity 246 +136 0.00% $ 371.46
MIRATI THERAPEUTICS INC
MRTX Equity 334 0 0.00% $ 260.52
GBP CASH
GBP Cash 127 0 0.00% $ 168.04
BLUEPRINT MEDICINES CORP
- Equity 110 0 0.00% $ 108.90
VIGIL NEUROSCIENCE INC CVR
DUMMY Equity 484 0 0.00% $ 24.20
KRW CASH
KRW Cash 9 0 0.00% $ 0.01
KORRO BIO INC CVR
KRRBIO Equity 420 0 0.00% $ 0.00
HKD/USD HKD Equity short -1,347,750 new −1,347,750 0.00% $ -13.57

Trades Nov 13, 2026 to Nov 16, 2026

Holding Ticker Action Before After Change Value
WUXI BIOLOGICS CAYMAN
2269 Closed 29,000 — −29,000 $ -172.785K
ABBOTT LABORATORIES ABT Sold 1,746 1,027 −719 $ -77.257K
PFIZER PFE Sold 7,359 6,812 −547 $ -15.786K
HKD/USD HKD New — -1,347,750 −1,347,750 $ -13.57

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up